NATCO Pharma Ltd. moves to reshape its capital structure

No specific split between debt reduction and capital expenditure has been disclosed. The exchange filing only confirms in-principle approval for a rights issue of fully paid-up equity shares; it does not earmark any amount for debt repayment or capex. ^[1]

The available rationale points instead to capital being raised for overseas/inorganic expansion, including potential acquisitions, rather than a defined debt-reduction programme or a specified capex budget. This is reported as the purpose of the rights issue, not as a quantified company allocation. ^[2]

As of Q1 FY27, the latest quarterly financial data shows:

• Consolidated debt-to-equity: 0.08x ^[3]
• Total debt: Rs 706.40 Crores ^[4]
• Total equity: Rs 9,221.10 Crores ^[5]

Analyst read: the 0.08x ratio indicates low balance-sheet leverage. Accordingly, unless the final offer document introduces a specific debt-paydown allocation, the rights issue appears more aligned with funding strategic expansion than with repairing an overleveraged balance sheet. The absence of a disclosed debt-versus-capex split means the deployment cannot yet be assessed quantitatively; the final letter of offer and subsequent utilisation disclosures are needed.

The rights issue ratio has not yet been announced. Natco Pharma’s Board has approved a rights issue of up to Rs 1,300 Crores, but the entitlement ratio, final issue price and number of shares remain to be determined ^[6]. The 21 September 2026 exchange filing confirms only in-principle approval from NSE and BSE ^[1].

Rights issue and dilution

Accordingly, exact dilution cannot yet be calculated. If the issue is subscribed in full:

• New shares = actual issue proceeds in Rs Crores / issue price per share in Rs
• Dilution for a shareholder who does not subscribe = new shares / post-issue shares

For example, the Rs 1,300 Crore figure is a cash-raising ceiling, not a share-count estimate. A higher issue price would result in fewer new shares and lower dilution.

Comparison with historical equity issuance

The reported equity share capital was:

The face value remained Rs 2 per share across the reported periods ^[9]. Thus, the observed equity base contracted modestly from FY23 to FY24 and then remained stable through Q1 FY27. The reported series covers FY23-FY26 plus Q1 FY27, rather than five completed fiscal years.

Analyst read: the proposed raise would be a clear departure from this recent pattern of stable paid-up capital. The Rs 1,300 Crore maximum is approximately 36.31 times the current Rs 35.80 Crore paid-up equity capital, derived from the proposed issue size ^[6] and current equity capital ^[8]. That comparison shows the scale of the fundraise, but it is not a 36.31-times dilution measure because the rights shares will be issued at a premium and the final share count is still unknown. A full dilution assessment requires the final issue price and entitlement ratio.

No confirmed SEBI filing date or deadline has been disclosed. The latest update confirms in-principle approvals from the exchanges, but does not specify when Natco Pharma will file the Letter of Offer with SEBI ^[10]. The Draft Letter of Offer had already been approved by the board on 9 September 2026 ^[11].

Before the record date can be announced, the following items remain unresolved:

• Issue price: yet to be finalised ^[11].
• Entitlement ratio: yet to be finalised; the number of rights shares will follow from the final issue terms ^[11].
• Applicable statutory and SEBI ICDR compliance/approvals: the rights issue remains subject to the regulatory and statutory framework under the SEBI ICDR Regulations ^[11].
• Record-date notice: the company has stated that the record date will be communicated separately; it has not yet been set ^[11].

Interpretation: the exchange in-principle approval is a procedural milestone, not confirmation that the SEBI LoF filing or record-date announcement has occurred. The evidence supports a conditional next step after finalising pricing and entitlement terms, but not a dated filing commitment. No additional specific condition precedent—such as NCLT approval of the demerger—has been identified as a stated prerequisite for announcing the rights-issue record date. The demerger’s NCLT filing is a separate pending process ^[11].